Pharmaceutical chaperones and proteostasis regulators in the therapy of lysosomal storage disorders: current perspective and future promises
Different approaches have been utilized or proposed for the treatment of lysosomal storage
disorders (LSDs) including enzyme replacement and hematopoietic stem cell transplant …
disorders (LSDs) including enzyme replacement and hematopoietic stem cell transplant …
Mucopolysaccharidosis type II (Hunter syndrome): Clinical and biochemical aspects of the disease and approaches to its diagnosis and treatment
S Mohamed, QQ He, AA Singh, V Ferro - Advances in Carbohydrate …, 2020 - Elsevier
Abstract Mucopolysaccharidosis type II (MPS II, Hunter syndrome) is a rare X-linked
lysosomal storage disease caused by mutations of the gene encoding the lysosomal …
lysosomal storage disease caused by mutations of the gene encoding the lysosomal …
[HTML][HTML] Checkpoint Inhibitor
S Mohamed, QQ He, AA Singh, V Ferro - checkpointinhibitor.com
Lysosomes are the organelles responsible for the intracellular degradation of
macromolecules such as oligosaccharides, glycolipids, proteins and glyco-proteins; their …
macromolecules such as oligosaccharides, glycolipids, proteins and glyco-proteins; their …
Synthèse d'aminocyclitols, inhibiteurs potentiels de glycosidases lysosomales, via des aldolases
FC Bres - 2010 - theses.hal.science
Les glycosidases sont des enzymes impliquées dans de nombreux processus biologiques.
Entre autres, elles sont responsables de la dégradation des déchets polysaccharidiques de …
Entre autres, elles sont responsables de la dégradation des déchets polysaccharidiques de …